2021 Multiple Sclerosis Updates: A Focus on New and Emerging Therapies, Best Practices in Clinical Management and Key Considerations During the COVID-19 Era– Tweetorial #1




Provided by Integrity Continuing Education, Inc.


Supported by independent educational grants from Biogen and EMD Serono, Inc.


Diagnosis of Multiple Sclerosis (MS)


Clinicians who treat patients with MS often do not initiate treatment early enough to avoid conversion to more progressive forms of MS or to identify the need for higher-efficacy treatment. They also may not be familiar with updated McDonald 2017 criteria designed to facilitate earlier diagnosis. Neurodegeneration begins at the onset of MS and accelerates rapidly. Because the brain has limited capacity to regenerate—especially with increasing age—timely diagnosis and prompt treatment are crucial to avoid or minimize deficits. It is estimated that 5%–10% of patients are misdiagnosed.  In one study, up to 18% of patients were given an incorrect diagnosis. Diagnosis is further complicated by the fact that there are no reliable evidence-based diagnostic biomarkers.

Through this initiative, participants will gain improved competence in diagnosing MS subtypes and knowledge of the updated McDonald diagnostic criteria to lead to earlier diagnosis and prompt treatment to prevent or delay irreversible neurologic damage.


Aaron Boster, MD
Founder and President
The Boster Center for Multiple Sclerosis
Columbus, Ohio


Barry A. Singer, MD
Director, The MS Center for Innovations in Care
St. Louis, Missouri

Release date: April 28, 2021
Expiration date: April 28, 2022
Estimated time to complete activity: 0.25 hour(s)



This program is intended for MS specialists, neurologists, internists, nurse practitioners, and physician assistants who are involved in the care of patients with MS.


Upon completion of this educational activity, participants should be able to:

  • Recognize the importance of early diagnosis in reducing disability progression using current diagnostic criteria

There are no fees for participating and receiving CME credit for this activity. During the period of April 28, 2021 through April 28, 2022, participants must:

  • Read the learning objectives and faculty disclosures
  • Complete the pretest
  • Study the educational activity
  • Complete the posttest and the evaluation form

A statement of credit will be issued only upon receipt of a completed activity evaluation form and a completed posttest with a score of 100%.




Physician Continuing Education

Accreditation Statement
Integrity Continuing Education, Inc. is accredited with commendation by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.


Integrity Continuing Education designates this enduring activity for a maximum of 0.25 AMA PRA Category 1 Credit(s). Physicians should claim only the credit commensurate with the extent of their participation in the activity.


For information about ACCME accreditation of this activity, please contact Integrity Continuing Education at (855) 835-4004 or cme@integrityce.com.


Integrity Continuing Education requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest they may have as related to the content of this activity. All identified conflicts of interest are thoroughly vetted by Integrity Continuing Education for fair balance, scientific objectivity of studies mentioned in the materials or used as the basis for content, and appropriateness of patient care recommendations.

The following faculty/planners reported the financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of these CME activities:

Aaron Boster, MD
Consulting Fees: EMD Serono, Genentech, Genzyme​, Novartis
Speakers’ Bureaus: EMD Serono, Genentech, Genzyme​

Barry A. Singer, MD
Consulting and/or Speaking Fees: AbbVie, Alexion, Bayer, Biogen, Bristol Myers Squibb (Celgene), EMD Serono, Janssen, Genentech, Greenwich Biosciences, Novartis, Roche, Sanofi Genzyme, Teva, TG Therapeutics
Institution Research Grants: AbbVie, Alkermes, Bayer, Biogen, MedImmune, Novartis, Roche, Sanofi Genzyme

The Integrity Continuing Education, Inc. planners/managers have nothing to disclose.


This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. Integrity Continuing Education, Inc. does not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of any organization associated with this activity. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.


When you participate in an online educational activity sponsored by Integrity Continuing Education, Inc., you will be asked for your name, degree(s), affiliation(s), street address, telephone number, fax number, and…(continued)


Minimum Processor: Intel Pentium 4, 2.33 + GHz (or equivalent)
Operating Systems: Windows XP, Windows 2000, Windows Vista, Windows 7, Windows 10, and Mac OS
Plug-in: Adobe® Flash® Player 10

  • Adobe® Flash® Player 10 plug-in should be downloaded
  • Click on the “Agree and install now” button after unchecking the optional McAfee Security Scan Plus

For optimal performance, the use of Internet Explorer below 8 is not recommended.

For a full listing of recommended operating systems, browsers, and system configurations, please click on the link below
Click here for more information on minimum system requirements.


The information provided at this activity is for continuing education purposes only and is not meant to substitute for the independent medical judgment of a physician relative to diagnostic and treatment options of a specific patient’s medical condition.



Continue to Pretest